

Director
Office of Nuclear Materials and Safeguards
United States Nuclear Regulatory Commission
Washington, D.C. 20555



DELNOR
HOSPITAL

975 North Fifth Avenue
St. Charles, Illinois 60174
(312) 564-3300

January 31, 1984

Dear Sirs,


I hereby submit our NRC license(#12-15842-01) for amendment to include two(2) items of Group VI, Iridium 192 and Iodine 125, for interstitial treatment of cancer.

Users will be Geoffrey L. Smoron, M.D. and James B. Gagnon, M.D. licensed under NRC # 12-06593-01.

The following is a description of special procedures for patients treated with byproduct materials as referenced to Item 20 of Regulatory Guide 10.8 for preparation of application for Medical Programs(Oct. 1980). We have followed instructions for Item 20, lettered a. thru g. as listed in the following paragraphs with the appropriate attachments.

Please find our check attached for amendment fee.

Sincerely,


John A. Taft, Jr.
President

B506190056 B50604
REG3 LIC30
12-15842-01 PDR

ATTACHMENT #2